Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of asthma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of asthma for each country,…

Clarivate Epidemiology’s coverage of asthma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of asthma for each country, as well…

Clarivate Epidemiology’s coverage of asthma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of asthma for each country, as well…

The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva),…

Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as ProAir HFA or its generics) and maintenance therapy to…

Two types of pharmacotherapy are used to treat adult asthma: rescue therapy and maintenance therapy. Rescue therapy (e.g., a SABA such as ProAir HFA or its generics) treats the acute symptoms of…

The asthma market in the EU5 is highly competitive. Many approved agents are available, including maintenance therapies—LABA/ICS FDCs (e.g., GSK’s Seretide and Relvar, AstraZeneca’s Symbicort…

Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the entry of LAMAs (e.g., BI’s Spiriva) and…

Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA) and maintenance therapy to prevent exacerbations by targeting…

Adult asthma is treated using two types of pharmacotherapy: rescue therapy to treat acute symptoms via bronchodilation (e.g., a SABA) and maintenance therapy to prevent exacerbations by targeting…

Dupixent (Sanofi / Regeneron), a first-in-class biologic that inhibits IL-4 / IL-13 signaling, was approved for the treatment of eosinophilic asthma and oral-corticosteroid-dependent asthma in…

The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva),…